1. Introduction {#sec1-cancers-11-00369}
===============

Colorectal cancer (CRC) represents the second most commonly diagnosed cancer in Europe, with 215,000 deaths in 2012 \[[@B1-cancers-11-00369],[@B2-cancers-11-00369]\].

Over the last two decades, the outcome of patients with metastatic CRC (mCRC) has significantly improved, reaching a median overall survival (mOS) of around 30 months, more than double that 20 years ago \[[@B3-cancers-11-00369],[@B4-cancers-11-00369]\].

This advancement may result from the contribution of a more aggressive systemic approach---including three-drug chemotherapy (CT) schemes and CT with targeted therapy combinations---together with a substantial change in surgical indication \[[@B5-cancers-11-00369],[@B6-cancers-11-00369],[@B7-cancers-11-00369]\].

In our study, we investigated the possible influence of tumour characteristics as well as the changes in treatment practice through the years, on the evolution of survival of mCRC patients.

2. Results {#sec2-cancers-11-00369}
==========

2.1. Demographics {#sec2dot1-cancers-11-00369}
-----------------

A total of 1702 patients with CRC were treated at our institution from 1999 to 2016.

Patients with localized CRC who received adjuvant CT only and those with mCRC who had never been treated with chemotherapy were excluded from the analysis.

Overall, 899 patients were available for the analysis, 788 of whom displayed a sufficient completeness of treatment and outcome data to be included in the survival analysis.

The median age at diagnosis was 62.58 years.

All main disease and treatment characteristics are summarized in [Table 1](#cancers-11-00369-t001){ref-type="table"}.

2.2. Treatment {#sec2dot2-cancers-11-00369}
--------------

Considering the whole population, patients who underwent surgery significantly increased (42% in Cohort A vs. 58% in Cohort B; *p* \< 0.009). A total of 203 patients only received hepatic surgery (93 in Cohort A vs. 110 in Cohort B). The details of surgery in the two cohorts are listed in [Table 2](#cancers-11-00369-t002){ref-type="table"} and [Table 3](#cancers-11-00369-t003){ref-type="table"}.

Eleven patients in Cohort B received hypertermic intraperitoneal chemotherapy (HIPEC) and/or pressurised intraperitoneal aerosol chemotherapy (PIPAC) procedures.

In the first line setting, two-drug CT containing oxaliplatin was the main choice in both cohorts (65.1% in Cohort A and 66.3% in Cohort B). Conversely, the use of irinotecan-based doublets was significantly higher in Cohort B (20.7%) compared with Cohort A (13.6%) in this setting, while it became the predominant CT adopted in both cohorts in the second line setting (54.3% in Cohort A and 56.7 % in Cohort B). Only 1% of patients received FOLFOXIRI regimen in Cohort B, especially in the first line setting. Conversely, the number of patients receiving monotherapy was significantly lower in all the treatment lines in more recent years.

Differences were also noted in the administration of anti-EGFR and anti-VEGF antibodies and an increase between the two cohorts in both the first and the second line settings was observed. Details of treatment administration in the two cohorts are presented in [Table 4](#cancers-11-00369-t004){ref-type="table"}.

2.3. Survival Analysis {#sec2dot3-cancers-11-00369}
----------------------

The survival analysis was carried out on 788 patients (46.3% in Cohort A and 53.7% in Cohort B). The median follow-up time was 24.7 months (23.8 months in Cohort A and 25.6 months in Cohort B).

The mOS was 32.0 months (95% confidence interval (CI); 28.8 to 35.3 months). Patients' survival in Cohort B was significantly longer compared with that in Cohort A (median 33.5 months vs. 29.2 months, respectively, HR 0.832; 95% CI 0.697--0.992; *p* = 0.041) ([Figure 1](#cancers-11-00369-f001){ref-type="fig"}).

Among patients included in the survival analysis, 456 underwent resection of hepatic and/or other metastatic sites, with a larger proportion of surgical patients in Cohort B (58% vs. 42%; *p* \< 0.009). While hepatic resection rates remained similar through the years (20.3% Cohort A vs. 24.1% Cohort B), resection of metastases at other sites with or without hepatic surgery was performed with increasing frequency (21.4% Cohort A vs. 33.9% Cohort B; *p* \< 0.005). In particular, the largest increase was in peritoneal surgery.

In the whole population, surgery in combination with CT allowed a significantly longer survival when compared with CT alone (median 58.5 months vs. 20.1 months, respectively, HR 0.262; 95% CI 0.216--0.316; *p* \< 0.0001). This advantage was maintained even when distinguishing between liver surgery and surgery of other sites, with or without hepatic surgery ([Figure 2](#cancers-11-00369-f002){ref-type="fig"}).

No differences in survival of patients who underwent surgery---in addition to a systemic treatment---were detected between cohorts (median 58.9 months vs. 58.2 months, HR 1.033; 95% CI, 0.779--1.369; *p* = 0.822) ([Figure 3](#cancers-11-00369-f003){ref-type="fig"}A).

After excluding patients who had hepatic resection alone, we found a significant improvement in survival in patients in Cohort B (25.7 months in Cohort A vs. 30.4 months in Cohort B; HR 0.796; 95% CI 0.656--0.967; *p* = 0.021) ([Figure 3](#cancers-11-00369-f003){ref-type="fig"}B).

We failed to demonstrate an improvement in OS in patients treated with CT alone (with or without targeted agents): mOS 18.9 months in Cohort A versus 20.7 months in Cohort B (HR 1.0; 95% CI 0.799--1.271; *p* = 0.948) ([Figure 3](#cancers-11-00369-f003){ref-type="fig"}C).

2.4. Prognostic Factors {#sec2dot4-cancers-11-00369}
-----------------------

The prognostic role of clinical characteristics was analysed by uni- and multivariate analysis ([Table 5](#cancers-11-00369-t005){ref-type="table"}).

At the multivariate analysis, a right-sided primary tumour and synchronous metastatic disease were found to be independent unfavorable prognostic factors. All these characteristics had a well-balanced distribution between cohorts ([Table 6](#cancers-11-00369-t006){ref-type="table"}).

In the whole population, a worse prognosis was observed for patients with right-sided compared with left-sided primary tumours---mOS 22.9 versus 38.6 months, respectively (HR 1.709; 95% CI 1.427--2.047; *p* \< 0.0001) ([Figure 4](#cancers-11-00369-f004){ref-type="fig"}A).

Survival seemed to increase in both left- and right-sided patients in Cohort B compared with Cohort A. However, the difference was statistically significant for right-sided tumours only (18.5 months Cohort A vs. 25.8 months Cohort B, HR 0.738; 95% CI 0.546--0.998; *p* = 0.044), without changes in the left-sided ones (34.5 months Cohort A vs. 37.5 months Cohort B; HR 0.883; 95% CI 0.638--1.223; *p* = 0.455) ([Figure 4](#cancers-11-00369-f004){ref-type="fig"}B,C).

After excluding surgery, a significant improvement was achieved in patients treated with systemic therapy only (15.8 months Cohort A vs. 22.1 months Cohort B, *p* = 0.041), while mOS in resected patients remained stable over time for right-sided tumours (49.6 months Cohort A vs. 48.2 months Cohort B, *p* = 0.736).

Median survival was 36.2 months for patients with metachronous disease and 30.0 months for patients with synchronous disease (HR 0.718; 95% CI 0.592--0.870; *p* = 0.001). Patients with synchronous disease trended to show better rates of survival in Cohort B (median 26.0 months Cohort A vs. 31.9 months Cohort B; HR 0.814; 95% CI 0.660--1.005; *p* = 0.05), while no significant improvement was recorded in metachronous disease (34.5 months Cohort A vs. 37.5 months Cohort B; HR 0.883; 95% CI 0.638--1.223; *p* = 0.455) ([Figure 5](#cancers-11-00369-f005){ref-type="fig"})

3. Discussion {#sec3-cancers-11-00369}
=============

Recent studies in mCRC have shown that new drug combinations allow patients to achieve mOS rates of around 30 months or more \[[@B5-cancers-11-00369],[@B6-cancers-11-00369],[@B7-cancers-11-00369]\]. However, these results might overestimate real world data because clinical study subjects generally represent a selected population with better prognostic characteristics compared with the general population. When currently used combinations were published in the early 2000s \[[@B8-cancers-11-00369],[@B9-cancers-11-00369],[@B10-cancers-11-00369]\], it became evident that mOS of mCRC patients could reach 21 to 24 months with CT and monoclonal antibodies (mAb). However, any comparison of those results with more recent data would be hindered by a number of biases.

In recent years, widespread awareness of the potential for cure has led to intensified treatment of mCRC, including multidisciplinary discussion and multimodality approach. Furthermore, molecular selection has gained an unquestionable role in exploiting EGFR inhibition and, in keeping with the rules in force, anti-EGFRs have also been introduced in first line treatments.

In this study, we looked into whether changes in practice might have influenced survival rates in an unselected population. The patients were treated at a single institute according to current guidelines and were retrospectively analysed. Two periods, for Cohort A until 2006, and for Cohort B from 2007 onwards, were compared.

The results of our analyses revealed that patients in Cohort B lived longer than patients in Cohort A. Kopetz et al. \[[@B11-cancers-11-00369]\] demonstrated that in patients diagnosed from 1998 to 2004, improvements in outcomes were mainly associated with an increase in surgery, whereas in the period from 2004 to 2006, the rise was related to advances in medical therapy. In our series, the percentage of patients who underwent surgery increased from 42% in Cohort A to 48% in Cohort B, while liver resection was stable at around 22%. This percentage was nearly the same as that of Kopetz et al.; however, they did not analyse extra-hepatic surgery data. A previous report from a multicenter study, including our own, highlighted the role of surgery of lung metastases in improving survival \[[@B12-cancers-11-00369]\]. Moreover, surgical management of mCRC has developed in recent years to include cytoreductive surgery of peritoneal metastases and HIPEC. These approaches are now evolving as new standards of treatment in highly specialized centers \[[@B13-cancers-11-00369]\]. In our study, the percentage of patients who underwent extra-hepatic surgery increased from 21% in Cohort A to 34% in Cohort B and the survival curves of these patients were similar to those of patients who had liver surgery alone. It is of note that, whereas the survival rates of patients receiving liver surgery alone did not differ between cohorts, there was a significant increase of survival in the subgroup of patients who had extra-hepatic surgery in recent years.

The main change observed in medical treatment practice, along with the introduction of mAb, was the adoption in the first-line of a two-drug in a larger percentage of patients in Cohort B, leaving the monotherapy to a subgroup of patients with poor prognosis. This reflects the updating of international guidelines, which previously considered asymptomatic patients with low burden disease as suitable for sequential schedules of monotherapy \[[@B4-cancers-11-00369]\]. More recently, a general strategy has evolved to consider a CT doublet with mAb as an appropriated choice, where the goal is disease control for patients for whom intensive treatment is not necessary \[[@B14-cancers-11-00369]\]. Even in unfit patients, capecitabine plus bevacizumab or a reduced-dose doublet of cytotoxics or anti-EGFR-containing therapy can be considered \[[@B3-cancers-11-00369]\].

Despite the evolution of medical strategies, if we compare survival rates of patients treated with CT alone, the increase of survival between the two cohorts was not significant in the whole population. However, considering patients with right-sided primary tumour, an independent negative prognostic factor, the survival of patients in Cohort B was significantly longer than in Cohort A. The prognostic role of tumour sideness has been known for a long time, however, recent studies have shed light on the biological causes of these differences \[[@B15-cancers-11-00369],[@B16-cancers-11-00369]\]. By separately analyzing patients with right-sided or left-sided tumours, we found that while survival increased in both groups, the difference was statistically significant in the right-sided group only. Furthermore, considering synchronous and metachronous metastatic groups, the improvement of survival in Cohort B was more evident for patients with synchronous metastatic disease.

4. Materials and Methods {#sec4-cancers-11-00369}
========================

4.1. Study Design {#sec4dot1-cancers-11-00369}
-----------------

The study is a retrospective, single institution experience, conducted on mCRC patients attending the Candiolo Cancer Institute from 1999 to 2016. All patients were treated, after informed consent was signed, according to institutional and national guidelines.

The aim of this study was to describe the evolution of survival of mCRC patients followed at a single institution over the past 17 years. All the patients were screened using the International Classification of Diseases 9th revision Clinical modification (ICD-9-CM) codes for colon and rectal cancer. Only patients receiving at least one course of therapy for mCRC were included. Both metachronous and synchronous metastatic disease presentations were taken into account. Metastatic disease was considered synchronous when diagnosed within six months after the initial diagnosis of CRC. For each patient, demographic and clinicopathological data were collected. We defined as a line of treatment all the therapies administered between the evidence of disease progression until further progression, even in the case of multimodality treatment.

All the descriptive analyses of the patients' characteristics included patients treated between January 1999 and November 2016. However, in order to minimize the risk of bias related to a small group of patients treated before 2001 (the date of the setting up of a multidisciplinary team for mCRC treatment) and to obtain a minimum follow-up period of two years, the survival analysis did not include patients diagnosed before 1 January 2001 or after 31 December 2014.

Overall survival was calculated from the date of diagnosis of metastatic disease until death, as notified by the registry office, or censored at the last follow-up visit. The median follow-up period was calculated on the basis of median survival without considering life status. In order to detect survival changes, patients were divided into two groups according to the year of metastatic disease diagnosis: Cohort A (between 2001 and 2006) and Cohort B (between 2007 and 2014). The cut off point was set at 2006 as this date coincided with the introduction of the molecular targeted agents in clinical practice.

4.2. Statistical Analysis {#sec4dot2-cancers-11-00369}
-------------------------

SPSS for Windows 20.0 (IBM SPSS, Chicago, IL, USA) was used for all statistical analyses. The differences between proportions were evaluated by the chi-square test with Yates correction, when appropriate. The Cox proportional hazards regression model was used and survival curves were plotted using Kaplan--Meier and compared by log-rank test. Overall survival was calculated from the date of diagnosis of metastatic disease until death, or censored at the last follow-up visit.

4.3. Ethics Approval and Consent to Participate {#sec4dot3-cancers-11-00369}
-----------------------------------------------

The study was performed in accordance with the Declaration of Helsinki. The development and the publication of this report was approved by the Institutional Review Board. The Medical Ethical Committee of the IRCCS Candiolo Cancer Institute confirmed that formal ethical approval was not required given the retrospective and observational nature of the study.

5. Conclusions {#sec5-cancers-11-00369}
==============

We realise that our study is limited by various biases related to the retrospective nature of our analyses. However, our results suggest that in current clinical practice, unless patients are classified as unfit for therapy, the therapeutic strategy is moving towards intensive treatment where at least two cytotoxic therapies are combined together with biological agents, and a multimodal approach in which surgery of metastatic sites is considered feasible. This approach seems appropriate to increase patient survival. In particular, it is likely that poor prognostic subgroups of mCRC patients would benefit from an integration of medical and surgical treatments in a '*continuum* of care' strategy.
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cancers-11-00369-t001_Table 1

###### 

Population characteristics.

  Characteristics                             Value                  
  ------------------------------------------- -------------- ------- -------
  **Primary tumour site**                     Right Colon    266     29.6%
  Left Colon (with rectum)                    622            69.1%   
  Unknown                                     11             1.4%    
  **Histological grade**                      G1--2          289     32.1%
  G3--4                                       234            26%     
  Not determined                              374            41.6%   
  **Chronology of metastases**                Metachronous   298     33.1%
  Synchronous                                 601            66.8%   
  **Metastatic sites at diagnosis**           Liver          605     67.2%
  Lung                                        216            24%     
  Lymph nodes                                 151            16.8%   
  Peritoneum                                  141            15.7%   
  Ovary/Uterus                                34             3.8%    
  Bone                                        11             1.2%    
  CNS                                         3              0.3%    
  **Molecular Characteristics**                                      
  **KRAS**                                    Wild type      213     23.7%
  Mutated                                     156            17.3%   
  Not determined                              530            58.9%   
  **NRAS**                                    Wild type      99      11%
  Mutated                                     8              0.9%    
  Not determined                              792            88%     
  **BRAF**                                    Wild type      140     15.6%
  Mutated                                     13             1.4%    
  Not determined                              746            82.9%   
  **PI3KCA**                                  Wild type      56      6.2%
  Mutated                                     10             1.1%    
  Not determined                              833            92.6%   
  **MSI**                                     MSS            167     18.6%
  MSI-H                                       14             1.6%    
  Not determined                              718            79.8%   
  **Treatment Characteristics**                                      
  **Chemotherapy**                            899            100%    
  **Surgery of metastases**                   456            50.7%   
  **Radiotherapy (palliative RT excluded)**   61             6.8%    
  **Locoregional treatments**                 18             2%      
  **HIPEC/PIPAC**                             11             1.2%    

Abbreviations: G = grade; CNS = central nervous system; MSS = microsatellite stable; MSI = microsatellite instable; RT = radiotherapy; HIPEC = hypertermic intraperitoneal chemotherapy; PIPAC = pressurised intraperitoneal aerosol chemotherapy.

cancers-11-00369-t002_Table 2

###### 

Liver surgery vs. surgery of other sites.

  Type of Surgery      Surgery of Metastases   Extra-Hepatic Surgery   Liver Surgery Alone                 
  -------------------- ----------------------- ----------------------- --------------------- ------- ----- -------
  **Cohort A**         191                     42%                     98                    21.4%   93    20.3%
  **Cohort B**         265                     58%                     155                   33.9%   110   24.1%
  **Total**            456                     50.7%                   253                   28%     203   22.6%
  ***p-*** **value**   \<0.009                 \<0.005                 \<0.91                              

cancers-11-00369-t003_Table 3

###### 

Surgery sites and distribution.

  -------------------------------------------------------------------
  Surgery          Patients (*N*)   *p*-Value\                
                                    (Chi Square)              
  ---------------- ---------------- -------------- ---------- -------
  **1st Line**                      Cohort A       Cohort B   

  **Surgery**      NO               235            241        0.041

  YES              180              243            \-         

  **Sites**        liver            118            124        0.071

  lymph nodes      1                10             \-         

  spleen           1                0              \-         

  ovary            7                14             \-         

  lung             13               27             \-         

  pelvis           15               15             \-         

  peritoneum       10               20             \-         

  CNS              0                1              \-         

  other sites      0                2              \-         

  adrenal gland    0                1              \-         

  multiple sites   15               29             \-         

  **2nd Line**                      Cohort A       Cohort B   

  **Surgery**      NO               352            409        0.896

  YES              63               75             \-         

  **Sites**        liver            20             27         0.489

  lymph nodes      3                2              \-         

  spleen           0                1              \-         

  ovary            2                5              \-         

  pelvis           8                4              \-         

  peritoneum       6                5              \-         

  lung             16               21             \-         

  CNS              4                1              \-         

  other sites      1                1              \-         

  adrenal gland    0                1              \-         

  multiple sites   3                6              \-         

  **3rd Line**                                                

  **Surgery**      NO               393            451        0.344

  YES              22               33             \-         

  **Sites**        liver            5              9          0.357

  lymph nodes      0                1              \-         

  ovary            1                0              \-         

  pelvis           3                0              \-         

  peritoneum       2                5              \-         

  lung             6                8              \-         

  CNS              1                4              \-         

  adrenal gland    0                1              \-         

  multiple sites   4                4              \-         

  **4th Line**                                                

  **Surgery**      NO               411            480        0.827

  YES              4                4              \-         

  **Sites**        liver            1              1          0.638

  pelvis           0                1              \-         

  lung             0                1              \-         

  multiple sites   1                0              \-         

  CNS              2                1              \-         
  -------------------------------------------------------------------

Abbreviation: CNS = central nervous system.

cancers-11-00369-t004_Table 4

###### 

Treatment characteristics.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Treatment Characteristics                1st Line      2nd Line      3rd Line      4th Line                                                              
  ---------------------------------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- ----------
  **Chemo therapy and targeted therapy**   FOLFOXIRI     none          3 (1.2%)      none          none          none          none          none          1 (1.1%)

  Oxaliplatin doublet                      152\          160\          60\           49\           40\           56\           35\           22\           
                                           (65.1%)       (66.3%)       (22.4%)       (18.5%)       (21.7%)       (32%)         (32.7%)       (24.4%)       

  Irinotecan doublet                       32\           50\           145\          151\          37\           39\           8\            20\           
                                           (13.6%)       (20.7%)       (54.3%)       (56.7%)       (20.1%)       (22.3%)       (7.5%)        (22.2%)       

  Monotherapy ^a^                          51\           27\           62\           66\           106\          71\           64\           38\           
                                           (21.7%)       (11.2%)       (23.3%)       (24.8%)       (57.6%)       (40.6%)       (59.8%)       (42.2%)       

  *p* value\                               \<0.0001      0.489         0.001         \<0.0001                                                              
  (chi square)                                                                                                                                             

  Anti-EGFR ^b^                            none          24\           8\            31\           41\           52\           13\           20\           
                                                         (23.7%) ^c^   (10.2%) ^c^   (24.8%) ^c^   (59.4%) ^c^   (53.6%) ^c^   (27.1%) ^c^   (40.1%) ^c^   

  Anti-VEGF ^b^                            6\            69\           2\            55\           4\            21\           6\            4\            
                                           (5.6%)        (76.6%)       (0.7%)        (20.6%)       (2.1%)        (12%)         (5.6%)        (4.4%)        

  *p* value\                               0.004         \<0.0001      \<0.0001      0.166                                                                 
  (chi square)                                                                                                                                             

  **Total \***                             **235**\      **241**\      **267**\      **266**\      **184**\      **175**\      **107**\      **90**\       
                                           **(56.6%)**   **(49.8%)**   **(71.8%)**   **(68.9%)**   **(65.2%)**   **(61.6%)**   **(63.9%)**   **(55.9%)**   

  **Chemo therapy + surgery**              FOLFOXIRI     none          2\            none          none          none          none          none          none
                                                                       (0.8%)                                                                              

  Oxaliplatin doublet                      110\          142\          15\           11\           3\            5\            none          1\            
                                           (67.9%)       (63.6%)       (38.4%)       (22.9%)       (27.3%)       (27.7%)                     (100%)        

  Irinotecan doublet                       14\           52\           20\           23\           3\            7\            none          none          
                                           (8.6%)        (23.3%)       (51.2%)       (47.9%)       (27.3%)       (39%)                                     

  Monotherapy ^a^                          38\           27\           4\            14\           5\            6\            2\            none          
                                           (23.4%)       (12.1%)       (10.2%)       (29.1%)       (45.4%)       (33.3%)       (100%)                      

  *p* value\                               \<0.0001      0.064         0.766         0.083                                                                 
  (chi square)                                                                                                                                             

  Anti-EGFR ^b^                            1\            10\           none          7\            3\            6\            none          none          
                                           (2.4%) ^c^    (9.7%) ^c^                  (22.5%) ^c^   (42.8%) ^c^   (40.0%) ^c^                               

  Anti-VEGF ^b^                            1\            49\           1\            6\            1\            none          none          none          
                                           (0.6%)        (21.9%)       (2.5%)        (22.2%)       (9%)                                                    

  *p* value\                               \<0.0001      0.007         0.422         \-                                                                    
  (chi square)                                                                                                                                             

  **Total \***                             **162**\      **223**\      **39**\       **48**\       **11**\       **18**\       **2**\        **1**\        
                                           **(39%)**     **(46.1%)**   **(10.5%)**   **(12.4%)**   **(3.9%)**    **(6.3%)**    **(1.2%)**    **(0.6%)**    

  **Surgery alone**                        18\           20\           24\           27\           11\           15\           2\            3\            
                                           (4.3%)        (4.1%)        (6.4%)        (9.4%)        (3.9%)        (5.3%)        (1.2%)        (1.8%)        

  **Not treated**                          none          none          42\           45\           76\           76\           57\           67\           
                                                                       (11.2%)       (11.6%)       (26.9%)       (26.7%)       (33.9%)       (41.6%)       
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* total of patients treated in the subgroup in this line; ^a^ percentage calculated relative to the number of patients treated in the subgroup for that line of therapy; ^b^ monoclonal antibody associated or not to chemotherapy; ^c^ percentage calculated relative to the number RAS or KRAS exon2 wild type or EGFR+ patients can be treated in this cohort and in this line.

cancers-11-00369-t005_Table 5

###### 

Univariate and multivariate analysis. CI---confidence interval.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                       Number of Patients\   Median Overall Survival (Months)   Univariate       Multivariate                    
                                                 (A vs. B)                                                                                                 
  ---------------------------------------------- --------------------- ---------------------------------- ---------------- -------------- ---------------- ----------
  **Primary tumour site**\                       236 vs. 542           22.9 vs. 38.6                      1.774\           \<0.0001       0.596\           \<0.0001
  **(Right vs. Left)**                                                                                    (1.470--2.140                   (0.491--0.723)   

  **Histological grade**\                        246 vs. 209           34.5 vs. 33.0                      1.058\           0.634          ns               ns
  **(G1--G2 vs. G3--G4)**                                                                                 (0.839--1.334)                                   

  **T status**\                                  51 vs. 554            43.9 vs. 38.6                      1.293\           0.178          ns               ns
  **(T1--T2 vs. T3--T4)**                                                                                 (0.889--1.878)                                   

  **N status**\                                  191 vs. 406           43.0 vs. 33.3                      1.344\           0.009          ns               ns
  **(N0 vs. N+)**                                                                                         (1.076--1.679)                                   

  **Chronology of mts**\                         536 vs. 252           30.0 vs. 36.2                      0.718\           0.001          0.764\           0.007
  **(Synchronous vs. Metachronous)**                                                                      (0.592--0.870)                  (0.628--0.929)   

  **KRAS Mutational Status**\                    185 vs. 122           42.0 vs. 34.4                      1.079\           0.626          ns               ns
  **(Wild Type vs. Mutated)**                                                                             (0.793--1.469)                                   

  **BRAF Mutational Status**\                    103 vs. 10            49.9 vs. 102.9                     0.696\           0.486          ns               ns
  **(Wild type vs. Mutated)**                                                                             (0.251--1.931)                                   

  **Liver mts at diagnosis**\                    530 vs. 258           30.7 vs. 34.5                      1.142\           0.167          ns               ns
  **(YES vs. NO)**                                                                                        (0.946--1.378)                                   

  **Lung mts at diagnosis**\                     194 vs. 594           30.0 vs. 32.7                      1.089\           0.412          ns               ns
  **(YES vs. NO)**                                                                                        (0.888--1.335)                                   

  **Lymph nodes mts at diagnosis**\              141 vs. 647           23.3 vs. 34.2                      1.617\           \< 0.0001      1.533\           \<0.0001
  **(YES vs. NO)**                                                                                        (1.296--2.018)                  (1.225--1.919)   

  **Peritoneal mts at diagnosis (YES vs. NO)**   121 vs. 667           31.0 vs. 32.7                      1.286\           0.048          ns               ns
                                                                                                          (1.009--1.638)                                   

  **Ovarian mts at diagnosis (YES vs. NO)**      32 vs. 756            42.4 vs. 31.8                      0.766\           0.267          ns               ns
                                                                                                          (0.478--1.226)                                   

  **Bone mts at diagnosis**\                     8 vs. 780             9.52 vs. 32.2                      4.370\           \<0.0001       4.427\           \<0.0001
  **(YES vs. NO)**                                                                                        (2.165--8.820)                  (2.181--8.984)   

  **CNS mts at diagnosis**\                      3 vs. 785             20.3 vs. 32.1                      2.731\           0.083          ns               ns
  **(YES vs. NO)**                                                                                        (0.876--8.513)                                   

  **Bone mts**\                                  80 vs. 707            28.3 vs. 32.2                      1.043\           0.774          ns               ns
  **(YES vs. NO)**                                                                                        (0.783--1.390)                                   

  **CNS mts**\                                   41 vs. 746            30.7 vs. 32.1                      1.137\           0.510          ns               ns
  **(YES vs. NO)**                                                                                        (0.776--1.664)                                   
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: CNS = central nervous system; mts = metastases; ns = not significant.
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###### 

Unfavourable prognostic factors distribution.

  Prognostic Factors     Cohort A   Cohort B   *p*-Value           
  ---------------------- ---------- ---------- ----------- ------- -------
  **Right Colon**        107        29.3%      129         30.5%   0.766
  **Left Colon**         252        69.0%      290         68.6%   
  **Synchronous mts**    250        68.5%      286         67.6%   0.791
  **Metachronous mts**   115        31.5%      137         32.4%   
  **Lymph nodes mts**    59         16.2%      82          19.4%   0.239
  **Bone mts**           3          0.8%       5           1.2%    0.615

Abbreviation: mts = metastases.

[^1]: These authors contributed equally to this work.
